OCWP
STRO icon

Owl Creek Wealth Partners’s Sutro Biopharma STRO Stock Holding History

Owl Creek Wealth Partners’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3K Hold
491
– – ﹤0.01% 694
2026
Q1 		$12.2K Buy
+491
New +$8.87K ﹤0.01% 726

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Owl Creek Wealth Partners's STRO Position: Q2 2026 in Review

Owl Creek Wealth Partners held its Sutro Biopharma (STRO) position steady in Q2 2026 at 491 shares worth $16.3K. The position accounts for ﹤0.01% of the portfolio, ranked #694.

Owl Creek Wealth Partners first reported a position in STRO in Q1 2026 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Owl Creek Wealth Partners held 491 shares of Sutro Biopharma worth $16.3K as of Q2 2026.
  • Owl Creek Wealth Partners left its Sutro Biopharma share count unchanged in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #694 holding.
  • Owl Creek Wealth Partners first reported a position in Sutro Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.